Vimarsana
Biggest News Aggregation in the World

Page 47 - Immunic Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Inc Today - Breaking & Trending Today

Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity - Vimarsana News

Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity

Share this article NEW YORK, May 6, 2021 /PRNewswire/ --  Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended March 31, 2021 and highlighted recent activity. "Our clinical program activities have continued unabated, with significant progress having recently been achieved for our lead asset, selective oral DHODH inhibitor, IMU-838," stated Daniel Vitt, Ph.D., Chief Executive Officer and Presi...

Kintara Therapeutics Appoints - GuruFocus.com - Vimarsana News

Kintara Therapeutics Appoints - GuruFocus.com

SAN DIEGO, May 4, 2021 SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executiv...

Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection - Vimarsana News

Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment...

DGAP-News: Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection - Vimarsana News

DGAP-News: Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection

(0) DGAP-News: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection 15.04.2021 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection - Preplanned Interim Analysis of 12-Week MRI Data from 10 mg IMU-838 Dose and Placebo, in Comb...

DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April - Vimarsana News

DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April

DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April vom 13.04.2021, 12:30 Uhr Bild: pixabay.com Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April 13.04.2021 / 12:30 Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April NEW YORK, April 13, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in t...